前列地尔和缬沙坦联合治疗慢性肾小球肾炎的治疗效果及可行性分析

Therapeutic effect and feasibility analysis of alprostadil and valsartan in the treatment of chronic glomerulonephritis

目的分析前列地尔和缬沙坦联合治疗慢性肾小球肾炎的临床效果。方法150例慢性肾小球肾炎患者,根据入院顺序分为实验组和对照组,每组75例。对照组患者接受缬沙坦治疗,实验组患者接受前列地尔联合缬沙坦治疗。比较两组患者治疗前后肾功能指标[血肌酐(Scr)、血尿素氮(BUN)、血清胱抑素C(Cys-C)],治疗前后凝血功能指标[血小板计数(PLT)、血红蛋白(Hb)、红细胞计数(RBC)],治疗效果。结果治疗后,实验组患者的Scr、BUN、Cys-C水平分别为(103.45±10.69)μmol/L、(4.69±1.75)mmol/L、(0.87±0.23)mg/L,均显著低于治疗前的(148.52±17.21)μmol/L、(9.72±2.23)mmol/L、(2.41±0.79)mg/L;对照组患者的Scr、BUN、Cys-C水平分别为(123.71±11.56)μmol/L、(6.39±1.32)mmol/L、(1.46±0.32)mg/L,均显著低于治疗前的(146.24±18.39)μmol/L、(9.56±2.15)mmol/L、(2.38±0.55)mg/L;且实验组患者的Scr、BUN、Cys-C水平均显著低于对照组,差异具有统计学意义(P<0.05)。治疗后,实验组患者的PLT、Hb、RBC水平分别为(205.34±10.74)×10^(9)/L、(164.07±10.36)g/L、(4.66±0.32)×10^(12)/L,均显著优于治疗前的(435.96±15.62)×10^(9)/L、(112.52±5.96)g/L、(3.83±0.52)×10^(12)/L;对照组患者的PLT、Hb、RBC水平分别为(214.08±12.69)×10^(9)/L、(155.84±6.98)g/L、(4.32±0.28)×10^(12)/L,均显著优于治疗前的(438.06±14.75)×10^(9)/L、(111.97±6.05)g/L、(3.79±0.48)×10^(12)/L;且实验组患者的PLT、Hb、RBC水平均显著优于对照组,差异具有统计学意义(P<0.05)。实验组患者的治疗总有效率为97.33%(73/75),显著高于对照组的78.67%(59/75),差异具有统计学意义(P<0.05)。结论在慢性肾小球肾炎患者临床治疗中,前列地尔和缬沙坦联合治疗方法具有先进性,值得推广。

Objective To analyze the clinical effect of alprostadil and valsartan in the treatment of chronic glomerulonephritis.Methods A total of 150 patients with chronic glomerulonephritis were divided into experimental group and control group according to the order of admission,with 75 cases in each group.The experimental group received alprostadil and valsartan combined treatment,and the control group received valsartan treatment alone.Patients in both groups were compared in terms of renal function indexes[serum creatinine(Scr),blood urea nitrogen(BUN),serum cystatin C(Cys-C)]before and after treatment,coagulation function indexes[platelet count(PLT),hemoglobin(Hb),red blood cell count(RBC)]before and after treatment,and therapeutic effect.Results After treatment,the levels of Scr,BUN,and Cys-C in the experimental group were(103.45±10.69)μmol/L,(4.69±1.75)mmol/L,and(0.87±0.23)mg/L,respectively,which were significantly lower than(148.52±17.21)μmol/L,(9.72±2.23)mmol/L,(2.41±0.79)mg/L before treatment;the levels of Scr,BUN,and Cys-C in the control group were(123.71±11.56)μmol/L,(6.39±1.32)mmol/L,and(1.46±0.32)mg/L,respectively,which were significantly lower than(146.24±18.39)μmol/L,(9.56±2.15)mmol/L,(2.38±0.55)mg/L before treatment;the levels of Scr,BUN,and Cys-C of the experimental group were significantly lower than those of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of PLT,Hb,and RBC in the experimental group were(205.34±10.74)×10^(9)/L,(164.07±10.36)g/L,and(4.66±0.32)×10^(12)/L,respectively,which were significantly better than(435.96±15.62)×10^(9)/L,(112.52±5.96)g/L,(3.83±0.52)×10^(12)/L before treatment;the levels of PLT,Hb,and RBC in the control group were(214.08±12.69)×10^(9)/L,(155.84±6.98)g/L,and(4.32±0.28)×10^(12)/L,which were significantly better than(438.06±14.75)×10^(9)/L,(111.97±6.05)g/L,(3.79±0.48)×10^(12)/L before treatment;the levels of PLT,Hb,and RBC of the experimental group were significantly better than those of the control group,and the difference was statistically significant(P<0.05).The total effective rate of treatment in the experimental group was 97.33%(73/75),which was significantly higher than 78.67%(59/75)in the control group,and the difference was statistically significant(P<0.05).Conclusion The combined treatment of alprostadil and valsartan is advanced in the clinical treatment of patients with chronic glomerulonephritis,and is worthy of promotion.